Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-02-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司第十一届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 7th meeting of the 11th Board of Directors of 金宇生物技术股份有限公司. It details decisions regarding the 2023 employee stock ownership plan and its management rules, including voting results and disclosures about board members' participation and recusal. The document does not contain financial statements or detailed financial data but rather reports on board decisions and governance matters. It is not an annual report, earnings release, or financial supplement. It is not a proxy solicitation or voting results announcement either, as it pertains to board meeting resolutions. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2023-02-28 Chinese
金宇生物技术股份有限公司2023年员工持股计划（草案修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed and lengthy text (15,000 characters) describing the 2023 Employee Stock Ownership Plan (员工持股计划) draft revision summary for 金宇生物技术股份有限公司. It includes detailed sections on the purpose, principles, participants, funding, stock sources, scale, purchase price, duration, lock-up periods, performance assessments, management, and governance of the employee stock ownership plan. It references relevant laws and regulations, shareholder approval requirements, and internal management structures. The document is not a brief announcement but a comprehensive plan document outlining the employee stock ownership plan's structure and rules. This type of document fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through an employee stock ownership plan. It is not an Annual Report, Audit Report, or Management Report, nor is it a voting result or proxy solicitation. It is not a regulatory filing or announcement of a report but the plan document itself. Therefore, the appropriate classification is CAP with high confidence.
2023-02-28 Chinese
金宇生物技术股份有限公司独立董事关于公司第十一届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's 2023 employee stock ownership plan and its management measures. It references compliance with laws, regulations, and company bylaws, and expresses agreement to submit the plan to the shareholders' meeting. The document is short (975 characters) and does not contain financial statements or detailed financial data. It is a governance-related opinion on board matters rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2023-02-28 Chinese
金宇生物技术股份有限公司第十一届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the Supervisory Board of a company regarding resolutions on the 2023 Employee Stock Ownership Plan and its management measures. It details the meeting attendance, voting procedures, and the decision to submit the proposals to the shareholders' meeting due to conflicts of interest among supervisors. The content focuses on governance and internal supervisory decisions rather than financial results, audit opinions, or regulatory filings. It is not a full report, earnings release, or proxy solicitation but an announcement of board/management decisions related to employee stock plans. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing (RNS) because it is a substantive announcement of board resolutions, not a certification or miscellaneous filing.
2023-02-28 Chinese
金宇生物技术股份有限公司2023年员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of an employee stock ownership plan (员工持股计划) for the year 2023 by 金宇生物技术股份有限公司. It includes comprehensive information about the plan's purpose, legal basis, participants, funding, stock source, scale, purchase price, lock-up periods, performance assessment, management, and governance structure. The document references relevant laws and regulations, detailed financial figures, and governance procedures related to the employee stock ownership plan. It is not a brief announcement or a simple notice but a substantive plan document outlining the structure and rules of the employee stock ownership plan. This type of document is best classified under Capital/Financing Update (CAP) because it relates to the company's financing activities through employee stock ownership plans, which affect capital structure and shareholder equity. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or proxy solicitation. Therefore, the most appropriate classification is CAP with high confidence.
2023-02-27 Chinese
金宇生物技术股份有限公司独立董事关于公司第十一届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at a board meeting, specifically regarding changes in the use of share repurchases and an employee stock ownership plan. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on governance and board-level decisions rather than financial results or regulatory filings. It is not a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement. The document is a board/management information type, as it relates to board meeting decisions and independent directors' opinions on corporate governance matters.
2023-02-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.